NeuX Technologies
NeuX Technologies is a Tampa, Florida-based health, wellness, and performance technology company developing Interactive Neuromuscular Stimulation (iNMS). Its flagship NXPro system combines electrical stimulation technology to support muscle activation, mobility, physical rehabilitation, strength, and athletic recovery. The company serves healthcare providers, rehabilitation professionals, fitness facilities, athletes, and wellness-focused consumers.
Visit WebsiteAbout NeuX Technologies
NeuX Technologies is a privately held health, wellness, and performance technology company headquartered in Tampa, Florida. The company develops Interactive Neuromuscular Stimulation (iNMS), a technology that combines pulsed direct current and alternating current to stimulate motor neurons and sensory nerves. Its flagship NXPro system is designed for use in physical training, rehabilitation, recovery, and performance optimization. NeuX positions its technology as a non-invasive approach to helping users improve muscle activation, mobility, strength, and functional movement.
The company serves a broad range of customers, including physical therapists, chiropractors, rehabilitation clinics, fitness facilities, sports performance centers, professional athletes, and individual wellness consumers. Its offerings include the NXPro stimulation system, treatment accessories, practitioner resources, and support for integrating the technology into training and rehabilitation programs. NeuX also promotes partnerships with fitness clubs and healthcare professionals seeking to expand their performance, recovery, and wellness services.
NeuX Technologies operates at the intersection of medical-device technology, rehabilitation, fitness, and human performance. Its commercial focus includes equipment sales, professional and facility adoption, practitioner relationships, and partnerships with performance and wellness organizations. The company emphasizes helping people move better and remain active throughout life. Specific therapeutic outcomes depend on the individual and application, and medical claims should be evaluated against appropriate clinical evidence and device indications.